The inventors have developed a panel of biomarkers, including various matrix metalloproteinases (MMPs) and tissue inhibitor matrix metalloproteinases (TIMPs), which identifies patients with early-stage changes that are indicative of heart failure. These biomarkers can be detected and measured by performing a simple, point-of-care blood test and provide earlier detection than the current diagnostic tests.
One million patients per year are diagnosed with heart failure upon presenting to the emergency room with symptoms such as shortness of breath. Troponin, NT-proBNP, and echocardiogram (ECG) are the current diagnostic tools for heart failure. None of the current tools are able to detect the disease in its earliest stages. There is a growing need for a preventative approach to identify patients earlier who are at risk for developing heart failure. The damage incurred by this disease is currently irreversible, so early detection and preventative care is of utmost importance. Early intervention will improve patient outcomes and results in significantly reduced costs.
Advantages: Earlier identification of patients at risk for diastolic heart failure
Key Words: Hypertrophic heart failure, congestive heart failure - CHF, heart failure with reduced ejection fraction – HFrEF, remodeling, hypertension, obesity, diabetes, diagnostic
Inventors: F.G. Spinale, M.R. Zile, R.E. Stroud
Patent Status: US Patent 8,790,871
MUSC-FRD Technology ID: P0619